PLoS Neglected Tropical Diseases (Mar 2023)

Impact of adverse events during community-wide mass drug administration for soil-transmitted helminths on subsequent participation-a Theory of Planned Behaviour analysis.

  • Kumudha Aruldas,
  • Gideon John Israel,
  • Jabaselvi Johnson,
  • Angelin Titus,
  • Malvika Saxena,
  • Saravanakumar Puthupalayam Kaliappan,
  • Rohan Michael Ramesh,
  • Judd L Walson,
  • Arianna Rubin Means,
  • Sitara S R Ajjampur

DOI
https://doi.org/10.1371/journal.pntd.0011148
Journal volume & issue
Vol. 17, no. 3
p. e0011148

Abstract

Read online

BackgroundExperiencing adverse events (AEs) during mass drug administration (MDA) could affect participation in future MDAs. This study aims to understand the potential influence of AEs during a community-wide MDA (cMDA) trial for soil-transmitted helminths (STH) in India on intention to participate in future cMDAs.MethodsThis study was conducted using a multi-method quantitative and qualitative approach among 74 participants who experienced an AE during STH cMDA and the 12 participants who subsequently refused cMDA treatment of the ongoing DeWorm3 trial. Path analysis and thematic analysis guided by the Theory of Planned Behaviour, was used.Principal findingsAmong 74 individuals who reported an AE, 12% refused treatment in the cMDA immediately subsequent to their AE and 4% refused in all subsequent cMDAs. Of these 74 individuals, 59 (80%) completed a survey and eight participated in in-depth interviews. A positive attitude towards deworming and perceived ability to participate in cMDA (perceived behavioural control) were significant predictors of intention to participate in cMDA (pConclusionsIntention to participate in future STH cMDAs was associated with caste (SC/ST) and family type (extended families). Therefore, community mobilization messages about potential AEs and their management may need to intentionally target non-SC/ST households, nuclear families, and those engaged in unskilled occupations to increase cMDA participation given the possibility of AEs occurring.Trial registrationNCT03014167, ClinicalTrials.gov.